Management of Patients with Metastatic Carcinoma of the Bladder
| Autor: | C. C. D. Van Der Rijt, T. A. W. Splinter |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Oncology
medicine.medical_specialty Gallium nitrate Chemotherapy business.industry medicine.medical_treatment Phases of clinical research Combination chemotherapy medicine.disease Metastatic carcinoma Clinical trial Transitional cell carcinoma Internal medicine medicine Urothelial cancer business medicine.drug |
| Zdroj: | Medical Radiology ISBN: 9783642643231 |
| DOI: | 10.1007/978-3-642-60258-0_28 |
| Popis: | Survival in untreated patients with metastatic carcinoma of the bladder is poor, the median survival being 3 months (Babaian et al. 1980). The current therapy of choice is combination chemotherapy, which is given with palliative intent, although some long-term survivors have been reported after achieving a complete response on chemotherapy. No clinical trials have been performed on treatment with chemotherapy versus best supportive care. Nevertheless, results from studies on prognostic factors and from phase III clinical trials support a beneficial effect of chemotherapy on survival in metastatic urothelial cancer. In most studies, data on urothelial cancer from different localizations have been clustered, as no differences in prognosis seem to exist between them. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|